OPEN END TURBO OPTIONSSCHEIN LONG - ASTRAZENECA | Market Closed - BOERSE MUENCHEN 02:25:17 2024-07-12 pm EDT | ||
| 3.27 EUR | +6.51% |
|
| Current month | -4.66% | ||
| 1 month | -7.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 3.27 | +6.51% |
| 24-07-11 | 3.07 | +0.66% |
| 24-07-10 | 3.05 | +5.68% |
| 24-07-09 | 2.886 | -3.80% |
| 24-07-08 | 3 | 0.00% |
Real-time BOERSE MUENCHEN
Last update July 12, 2024 at 02:25 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Goldman Sachs |
| WKN | GP7Q59 |
| ISIN | DE000GP7Q593 |
| Date issued | 2023-07-07 |
| Strike | 9,538 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.784 € |
|---|---|
| Lowest since issue | 0.265 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
159.2
USD
Average target price
177.2
USD
Spread / Average Target
+11.26%
- Stock Market
- Certificates
- Certificat
